Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Inducible brown adipose tissue, or beige fat, is anabolic for the skeleton.

Endocrinology | 2013

It is known that insulin resistance and type 2 diabetes mellitus are associated with increased fractures and that brown adipose tissue (BAT) counteracts many if not all of the symptoms associated with type 2 diabetes. By the use of FoxC2(AD)(+/Tg) mice, a well-established model for induction of BAT, or beige fat, we present data extending the beneficial action of beige fat to also include a positive effect on bone. FoxC2(AD)(+/Tg) mice are lean and insulin-sensitive and have high bone mass due to increased bone formation associated with high bone turnover. Inducible BAT is linked to activation of endosteal osteoblasts whereas osteocytes have decreased expression of the Sost transcript encoding sclerostin and elevated expression of Rankl. Conditioned media (CM) collected from forkhead box c2 (FOXC2)-induced beige adipocytes activated the osteoblast phenotype and increased levels of phospho-AKT and β-catenin in recipient cells. In osteocytes, the same media decreased Sost expression. Immunodepletion of CM with antibodies against wingless related MMTV integration site 10b (WNT10b) and insulin-like growth factor binding protein 2 (IGFBP2) resulted in the loss of pro-osteoblastic activity, and the loss of increase in the levels of phospho-AKT and β-catenin. Conversely, CM derived from cells overexpressing IGFBP2 or WNT10b restored osteoblastic activity in recipient cells. In conclusion, beige fat secretes endocrine/paracrine activity that is beneficial for the skeleton.

Pubmed ID: 23696565 RIS Download

Associated grants

  • Agency: NIDDK NIH HHS, United States
    Id: R24 DK092759
  • Agency: NIA NIH HHS, United States
    Id: R01 AG028935
  • Agency: NIAMS NIH HHS, United States
    Id: R01 AR045433
  • Agency: NIA NIH HHS, United States
    Id: R01 AG040217
  • Agency: NIDDK NIH HHS, United States
    Id: P60 DK020572
  • Agency: NIDDK NIH HHS, United States
    Id: DK092759
  • Agency: NIA NIH HHS, United States
    Id: AG028935
  • Agency: NIDDK NIH HHS, United States
    Id: P30 DK020572
  • Agency: NIDDK NIH HHS, United States
    Id: 5P60 DK20572
  • Agency: NIAMS NIH HHS, United States
    Id: AR45433
  • Agency: NIAMS NIH HHS, United States
    Id: R01 AR061164

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Wnt-10b (N-19) (antibody)

RRID:AB_2215113

This polyclonal targets Wnt-10b (N-19)

View all literature mentions

IGFBP2 (M-18) (antibody)

RRID:AB_2264597

This polyclonal targets IGFBP2 (M-18)

View all literature mentions

Phospho-Akt (Ser473) Antibody (antibody)

RRID:AB_329825

This polyclonal targets Phospho-Akt (Ser473)

View all literature mentions

Akt Antibody (antibody)

RRID:AB_329827

This polyclonal targets Akt

View all literature mentions